Idelalisib- a PI3Kδ targeting agent for B-cell malignancies.

about

Novel Drugs in Follicular Lymphoma Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.Idelalisib induces PUMA-dependent apoptosis in colon cancer cells.

P2860

Q28076335-8A4CE58B-FDA9-41EA-945B-6DEBCB6F4CEF Q37079141-D8849CA2-5307-49DC-A270-6F157545018B Q37701548-91AC2384-1BF5-4649-A377-822F7328FD69

P2860

Idelalisib- a PI3Kδ targeting agent for B-cell malignancies.

Item

http://www.wikidata.org/entity/Q38364936

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Idelalisib- a PI3Kδ targeting agent for B-cell malignancies.

@en

type

Item

label

Idelalisib- a PI3Kδ targeting agent for B-cell malignancies.

@en

prefLabel

Idelalisib- a PI3Kδ targeting agent for B-cell malignancies.

@en

P1476

Idelalisib- a PI3Kδ targeting agent for B-cell malignancies.

@en

P2093

Binay K Shah

http://www.w3.org/2001/XMLSchema#string

Dipesh Uprety

http://www.w3.org/2001/XMLSchema#string

Yvonne G Hewett

http://www.w3.org/2001/XMLSchema#string

P2860

p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes

Protein kinases and phosphatases in the control of cell fate

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.

PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.

A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL).

Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics.

P304

284-288

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1078155215572933

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25712626

http://www.w3.org/2001/XMLSchema#string

Idelalisib- a PI3Kδ targeting agent for B-cell malignancies.

about

P2860

P2860

Idelalisib- a PI3Kδ targeting agent for B-cell malignancies.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698